Program in Pharmacoepidemiology

Publications

  1. Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real-World Data: The INVESTED-Medicare Linkage Study - PubMed. Clin Pharmacol Ther. 2026
  2. Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study - PubMed. Cardiovasc Diabetol. -2026
  3. An Observational Study of Post-hip Fracture Outcomes in Older Adults with Type 2 Diabetes - PubMed. J Gen Intern Med. -2026
  4. Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study - PubMed. Diabetes Obes Metab. -2026
  5. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations - PubMed. Diabetes Care. -2026
  6. Diabetic Ketoacidosis Risk in Sodium-Glucose Cotransporter 2 Inhibitors versus Glucagon-Like Peptide-1 Receptor Agonists Initiators with CKD Stages 3-4 and Type 2 Diabetes - PubMed. Kidney360. -2026.
  7. Comparative Effectiveness of Current Glucose-lowering Medications in Type 2 Diabetes Mellitus: Emulation of a Modified GRADE Trial - PubMed. J Gen Intern Med. -2026.
  8. Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes - PubMed. Ann Intern Med. -2026.
  9. Comparative healthcare resource utilization and costs of empagliflozin and GLP-1 receptor agonists in type 2 diabetes - PubMed. Diabetes Obes Metab. -2026.
  10. GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study - PubMed. -Diabetes Obes Metab. -2026. 
  11. Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes - PubMed. – Diabetes Care. -2025.
  12. Machine learning for predicting cardiovascular events in older adults with type 2 diabetes using Medicare claims and electronic health records - PubMed. J Clin Epidemiol. -2025.
  13. Overall uptake and racial, ethnic, and socioeconomic disparities in the use of continuous glucose monitoring devices among insulin-treated older adults with type 2 diabetes. Diabetes Care -2025
  14. Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study. Diabetes Obes Metab. -2025
  15. Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications among Patients with Chronic Kidney Disease with and without Type 2 Diabetes  Kidney Med. -2025
  16. Trends in Utilization of Glucose- and Weight-Lowering Medications after Tirzepatide Approval in the United States: A Population-Based Cohort Study. Ann Intern Med. -2025
  17. Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients with Type 2 Diabetes JAMA Intern Med. -2025
  18. Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors JAMA Intern Med. -2025
  19. Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes JAMA Ophthalmol. -2024
  20. Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study BMJ. - 2024
  21. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study​ BMJ. - 2024
  22. Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes Diabetes Care. -2024
  23. Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study J Gen Intern Med. -2024
  24. ​Effectiveness and safety of empagliflozin: final results from the EMPRISE study Diabetologia. -2024
  25. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study Cardiovasc Diabetol. -2024
  26. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients with Type 2 Diabetes JAMA Intern Med. -2024
  27. High-Dose vs. Standard-Dose Influenza Vaccine and Cardiopulmonary Hospitalization or Mortality: Emulating the INVESTED Trial Using Insurance Claims Data Clin Pharmacol Ther. -2024
  28. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes Kidney Int. - 2023
  29. Risk of severe hypoglycemia with newer second-line glucose-lowering medications in older adults with type 2 diabetes stratified by known indicators of hypoglycemia risk J Gerontol A Biol Sci Med Sci. - 2023 
  30. Achieving comparability in glycemic control between antidiabetic treatment strategies in pregnancy when using real world data Pharmacoepidemiol Drug Saf. - 2023
  31. Successful implementation of a stakeholder engagement program for pharmacoepidemiologic research Pharmacoepidemiol Drug Saf. - 2023
  32. ​Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes  Diabetes Care. - 2023
  33. Stratified analysis in comparative effectiveness studies that emulate randomized trials​ Pharmacoepidemiol Drug Saf. - 2023
  34. Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom Diabetes Obes Metab. - 2023 
  35. Antidiabetes medication initiation trends in US adults with cirrhosis and type 2 diabetes: A nationwide study​ Diabetes Obes Metab. - 2023
  36. Safety of SGLT2i with regard to bone and mineral metabolism in patients with CKD Curr Opin Nephrol Hypertens. - 2023
  37. Continuous Glucose Monitoring in Adults with Diabetes in Clinical Practice: Increased Access and Education Needed  J Gen Intern Med. - 2023
  38. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels JAMA Intern Med. - 2023 
  39. Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study Clin J Am Soc Nephrol - 2023 
  40. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure Diabetes Care. - 2023​
  41. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Ann Intern Med. - 2022 
  42. The use of glucose-lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States Endocrinol Diabetes Metab - 2022 
  43. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study: Diabetes Obes Metab. - 2022
  44. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes: Pharmacoepidemiol Drug Saf. - 2022​
  45. Prevalence of Avoidable and Bias-Inflicting Methodological Pitfalls in Real-World Studies of Medication Safety and Effectiveness: Clin Pharmacol Ther. -2022
  46. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes: Clin Gastroenterol Hepatol. - 2022
  47. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes: Am J Kidney Dis. - 2022
  48. Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data: Pharmacoepidemiol Drug Saf. - 2022
  49. Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease: Clin Diabetes. - 2022
  50. Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer: J Card Fail. - 2022
  51. Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries: Diabetes Care. - 2022
  52. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study: Ann Intern Med. - 2022​
  53. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes: Pharmacoepidemiol Drug Saf. - 2022
  54. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes: JAMA Netw Open - 2021
  55. Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study: Diabetes Care. - 2021
  56. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease: Ann Intern Med. - 2021
  57. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults: Diabetes Care. - 2021
  58. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments: Endocr Rev. - 2021
  59. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy:  Circulation. -2021 
  60. Validation of obesity-related diagnosis codes in claims data: Diabetes Obes Metab.​ - 2021
  61. The modifying effects of adiposity on the cardiovascular safety of sulphonylureas: Diabetes Obes Metab. - 2021
  62. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States: Diabetes Obes Metab.​ - 2021
  63. How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools: BMJ Open. - 2021
  64. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA: Diabetes Care. - 2021
  65. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy: Circulation. - 2021
  66. A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes: Endocrinol Diabetes Metab.​ - 2021
  67. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease: Ann Intern Med.​ - 2021
  68. Comparative effectiveness of empagliflozin in reducing total cardiovascular events in the empagliflozin comparative effectiveness and safety (EMPRISE) study: Journal of the American College of Cardiology - 2021
  69. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease: Clin J Am Soc Nephrol​ -2020
  70. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study: Ann Intern Med.- 2020
  71. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018: Diabetes Care. - 2020
  72. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis: Cardiovascular Diabetology. - 2020
  73. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea: JAMA Dermatol. - 2020
  74. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study: BMJ. - 2020
  75. Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications: Value Health. - 2020
  76. Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes: Diabetes Obes Metab. - 2020
  77. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care: Endocrinol Diabetes Metab. - 2019
  78. Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data: Diabetes Obes Metab. - 2019
  79. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study: Ann Intern Med. - 2019
  80. Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing: Clin Kidney J. - 2019
  81. Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care: Diabetes Obes Metab. - 2019
  82. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: Circulation.​ - 2019
  83. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study: Ann Intern Med. - 2019
  84. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors: Diabetes Obes Metab. 2019